Acquisition kickstarted Eli Lilly's oncology focus
The biggest acquisition in the history of the company led to Eli Lilly’s intense focus on oncology drugs, which is now nearing its climax. The US company’s Scandinavian head has talked to MedWatch about the crown jewel of the group’s pipeline and the ubiquitous presence of a certain rival.
BY STEFAN SINGH KAILAY
Eli Lilly has truly joined the choir of drug companies that swear by the potential of cancer drugs. It is a bulging pipeline and massive expectations for three late-stage candidates, in particular, that make the company go all in.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
This is Eli Lilly’s focus
For abonnenter
